Skip to main content
NCBI home page
Journal of the American Aging Association logoLink to Journal of the American Aging Association
. 2000 Jan;23(1):33–40. doi: 10.1007/s11357-000-0005-x

Age-dependent accumulation of advanced glycation endproducts is accelerated in combined hyperlipidemia and hyperglycemia, a process attenuated by L-arginine

Adriana Georgescu 1, Doina Popov 1,✉
PMCID: PMC3455358  PMID: 23604797

Abstract

In this study we have investigated the occurrence of “classical” Amadori rearrangement products of AGE-proteins in the vascular mesenteric bed and in the lens of Golden Syrian hamsters (12 weeks old) rendered simultaneous hyperlipidemics-diabetics (HD), or hyperlipidemics (H) for 24 weeks. For the next 4 weeks the hamsters in HD and H groups received by gavage a solution of 3 mM L-arginine, with the intent to look for the potential effects of L-arginine on the fluorescence of tissular AGE-proteins. Age-matched normal hamsters were used as controls (C). The AGE-products of proteins, and the AGE-collagen isolated from the mesenteric bed were quantitated by fluorescence spectroscopy at ex: 370 nm/em: 440 nm. The results showed that: (i) compared to the fluorescence levels of AGE-proteins detected at C goup, in HD group the fluorescence of AGE-proteins was found 2.78 and 7.41 fold increased in the vascular mesenteric bed and lens, respectively; (ii) in H group the fluorescence of AGE-proteins was 2.36 fold augumented in the vascular mesenteric bed, and 5.43 fold in the lens (versus the C goup); (iii) the aging occurring during the 24 weeks of the experiment induced a small increase in AGE-proteins fluorescence in both mesentery (1.76 fold) and lens (3.83 fold), compared to the levels measured in C group at the inception of the study (12 weeks old hamsters); (iv) the fluorescence of AGE-proteins in the vascular mesenteric bed and in the lens of hamsters in HD and H groups correlated with the increase in circulating plasma glucose and cholesterol concentrations throughout the experiment; (v) L-arginine dietary supplementation in HD and H groups, diminished the AGE-collagen fluorescence in the mesentery to ∼ 35% and ∼ 17%, respectively; in the lens the fluorescence of AGE-proteins was reduced to 65–70% of the levels found in HD and H groups (at 24 weeks). This study showed for the first time that simultaneous hyperlipidemia-hyperglycemia induced an enhanced accumulation of fluorescent AGE-proteins in the mesentery and lens (comparatively to the effect of hyperlipidemia and of chronological aging monitored during the experiment), and that in vivo L-arginine administration decreased the fluorescence of tissular AGE-proteins (AGE-collagen included). The latter observation may bring another area of potential intervention in the adjunct efforts to find out inhibitors of AGE formation, and thus to reduce the increased levels of AGE-proteins accumulated in tissues when diabetes is additionally complicated with atherosclerosis.

Full Text

The Full Text of this article is available as a PDF (662.7 KB).

References

  • 1.Ashley Booth A., Khalifah R. G., Todd P., Hudson B.G. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs) J. Biol. Chem. 1997;272:5430–5437. doi: 10.1074/jbc.272.9.5430. [DOI] [PubMed] [Google Scholar]
  • 2.Westwood, M. E., and Thornaley, P.J.: Glycation and advanced glycation endproducts, in The glycation Hypothesis of Atherosclerosis, edited by Colaco, C., Landers Bioscience, 1997, pp. 57–87.
  • 3.Monnier V.M., Cerami A. Nonenzymatic browning in vivo: Possible process for aging of long lived proteins. Science. 1981;211:491–493. doi: 10.1126/science.6779377. [DOI] [PubMed] [Google Scholar]
  • 4.Wu J.T. Advanced glycosylation end products: a new disease marker for diabetes and aging. J. Clin. Lab. Analysis. 1993;7:252–255. doi: 10.1002/jcla.1860070503. [DOI] [PubMed] [Google Scholar]
  • 5.Haitoglu, C.S., Tsilibary, E.C., Brownlee, M., Charonis, A.S.: Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J. Biol. Chem., 267: 12404–12407, 1992. [PubMed]
  • 6.Swamy M.S., Abraham A., Abraham E.C. Glycation of human lens proteins: preferential glycation of αA subunits. Exp. Eye. Res. 1992;54:337–345. doi: 10.1016/0014-4835(92)90046-U. [DOI] [PubMed] [Google Scholar]
  • 7.Wu J.T. Review of diabetes: identification of markers for early detection, glycemic control, and monitoring clinical complications. J. Clin. Lab. Analysis. 1993;7:293–300. doi: 10.1002/jcla.1860070510. [DOI] [PubMed] [Google Scholar]
  • 8.Bucala R., Vlassara H., Cerami A. Advanced glycosylated endproducts:role in diabetic and nondiabetic vascular disease. Drug Develop. Res. 1994;32:77–89. doi: 10.1002/ddr.430320204. [DOI] [Google Scholar]
  • 9.Bucala R., Makita Z., Vega G., Grundy S., Koschinsky T., Cerami A., Vlassara H. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc. Natl. Acad. Sci. USA. 1994;91:9441–9445. doi: 10.1073/pnas.91.20.9441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Fu M.X., Requena J.R., Jenkins A.J., Lyons T.J., Baynes J.W., Thorpe S.R. The advanced glycation end-product Nɛ-(carboxymethyl)-lysine, is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem. 1996;271:9982–9986. doi: 10.1074/jbc.271.33.19641. [DOI] [PubMed] [Google Scholar]
  • 11.Nakamura Y., Horii Y., Nishino T., Shiiki H., Sakaguchi Y., Kagoshima T., Dohi K., Makita Z., Vlassara H., Bucala R. Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus. Am. J. Pathol. 1993;143:1649–1656. [PMC free article] [PubMed] [Google Scholar]
  • 12.Hunt J.V. The assessment of protein glycation in human atherosclerotic plaques by affinity chromatography. Redox Rep. 1996;2:5–8. doi: 10.1080/13510002.1996.11747020. [DOI] [PubMed] [Google Scholar]
  • 13.Sakata N., Imanaga Y., Meng J., Tachikawa Y., Takebayashi S., Nagai R., Horiuchi S., Itabe H., Takano T. Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. Atherosclerosis. 1998;141:61–75. doi: 10.1016/S0021-9150(98)00149-X. [DOI] [PubMed] [Google Scholar]
  • 14.Timmerstein M.A., Pierce C.A., Leraas T.L., Fariss M.W. A fluorescence plate reader assay for monitoring the susceptibility of biological samples to lipid peroxidation. Anal. Biochem. 1998;265:246–252. doi: 10.1006/abio.1998.2907. [DOI] [PubMed] [Google Scholar]
  • 15.Nistor A., Bulla A., Filip D.A., Radu A. The hyperlipidemic hamster as a model of experimental atherosclerosis. Atherosclerosis. 1987;68:159–173. doi: 10.1016/0021-9150(87)90106-7. [DOI] [PubMed] [Google Scholar]
  • 16.Popov D., Sima A., Stern D., Simionescu M. The pathomorphological alterations of endocardial endothelium in experimental diabetes and diabetes associated with hyperlipidemia. Acta. Diabetol. 1996;33:41–47. doi: 10.1007/BF00571939. [DOI] [PubMed] [Google Scholar]
  • 17.Simionescu M., Popov D., Sima A., Hasu M., Costache G., Faitar S., Vulpanovici A., Stancu C., Stern D., Simionescu N. Pathobiochemistry of combined diabetes and atherosclerosis studied on a novel animal model. Am. J. Pathol. 1996;148:997–1014. [PMC free article] [PubMed] [Google Scholar]
  • 18.Howard B.V. Lipoprotein metabolism in diabetes mellitus. J.Lipid Res. 1987;28:613–628. [PubMed] [Google Scholar]
  • 19.MacDonald E., Lee W.K., Hepburn S., Bell J., Scott P.J.W., Dominiczak M.H. Advanced glycosylation end products in the mesenteric artery. Clin. Chem. 1992;38:530–533. [PubMed] [Google Scholar]
  • 20.Rumble J.R., Cooper M.E., Soulis T., Cox A., Wu L., Youssef S., Jasik M., Jerums G., Gilbert R.E. Vascular hypertrophy in experimental diabetes-Role of advanced glycation end products. J.Clin. Invest. 1997;99:1016–1027. doi: 10.1172/JCI119229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Cooper M.E., Rumble J., Komers R., He-Cheng D., Jandeleit K., Sheung-To C. Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes. 1994;43:1221–1228. doi: 10.2337/diab.43.10.1221. [DOI] [PubMed] [Google Scholar]
  • 22.Nakayama H., Mitsuhashi T., Kuwajima S., Aoki S., Kuroda Y., Itoh T., Nakagawa S. Immunochemical detection of advanced glycation end products in lens crystallins from streptozotocin-induced diabetic rat. Diabetes. 1993;42:345–350. doi: 10.2337/diab.42.2.345. [DOI] [PubMed] [Google Scholar]
  • 23.Scalbert P., Birlouez-Aragon I. Relationship between lens protein glycation and membrane structure in human cataract. Exp. Eye. Res. 1993;56:335–340. doi: 10.1006/exer.1993.1043. [DOI] [PubMed] [Google Scholar]
  • 24.Duhaiman A. S. Glycation of human ens proteins from diabetic and (nondiabetic) senile cataract patients. Glycoconj. J. 1995;12:618–621. doi: 10.1007/BF00731255. [DOI] [PubMed] [Google Scholar]
  • 25.Weninger M., Zi Z., Lubec B., Szalay S., Hoger H., Lubec G. L-Arginine reduces glomerutar basement membrane collagen Nɛ-carboxymethyllysine in the diabetic db/db mouse. Nephron. 1992;62:80–83. doi: 10.1159/000187000. [DOI] [PubMed] [Google Scholar]
  • 26.Bellmut M.J., Portero M., Pamplona R., Muntaner M., Prat J. Age-related fluorescence in rat lung collagen. Lung. 1995;173:177–185. doi: 10.1007/BF00175658. [DOI] [PubMed] [Google Scholar]
  • 27.Odetti P., Traverso N., Cosso L., Noberasco G., Pronzato M.A., Marinari U.M. Good glycaemic control reduces oxidation and glycation end-products in collagen of diabetic rats. Diabetologia. 1996;39:1440–1447. doi: 10.1007/s001250050596. [DOI] [PubMed] [Google Scholar]
  • 28.Miksik I., Deyl Z. Post-translational non-enzymatic modification of proteins.II. Separation of selected protein species after glycation and other carbonyl-mediated modifications. J.Chromatogr. B Biomed. Sci. Appl. 1997;699:311–345. doi: 10.1016/S0378-4347(97)00233-8. [DOI] [PubMed] [Google Scholar]
  • 29.Yanagisawa K., Makita Z., Shiroshita K., Ueda T., Fusegawa T., Kuwajima S., Takeuchi M., Koike T. Specific fluorescence assay for advanced glycation endproducts in blood and urine of diabetic patients. Metabolism. 1998;47:1348–1353. doi: 10.1016/S0026-0495(98)90303-1. [DOI] [PubMed] [Google Scholar]
  • 30.Abiko T., Abiko A., Ishiko S., Takeda M., Horiuchi S., Yoshida A. Relationship between autofluorescence and advanced glycation endproducts in diabetic lenses. Exp. Eye Res. 1999;68:361–366. doi: 10.1006/exer.1998.0615. [DOI] [PubMed] [Google Scholar]
  • 31.Henle T., Deppisch R., Beck W., Hergesell O., Hansch G.M., Ritz E. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol. Dial. Transplant. 1999;14:1968–1975. doi: 10.1093/ndt/14.8.1968. [DOI] [PubMed] [Google Scholar]
  • 32.Koefoed Theil P., Hansen T., Larsen M., Pedersen O., Lund-Andersen H. Lens autofluorescence is increased in newly diagnosed patients with NIDDM. Diabetologia. 1996;39:1524–1527. doi: 10.1007/s001250050608. [DOI] [PubMed] [Google Scholar]
  • 33.Miksik I., Zicha J., Kunes J., Devi Z. Glycation of collagen in hypertriglyceridemic rats. Life Sci. 1997;60:2119–2127. doi: 10.1016/S0024-3205(97)00221-X. [DOI] [PubMed] [Google Scholar]
  • 34.Meng J., Sakata N., Takebayashi S., Asano T., Futata T., Nagai R., Ikeda K., Horiuchi S., Myint T., Taniguchi N. Glycoxidation in aortic collagen from STZ-induced diabetic rats and its relevance to vascular damage. Atherosclerosis. 1998;136:355–365. doi: 10.1016/S0021-9150(97)00238-4. [DOI] [PubMed] [Google Scholar]
  • 35.Meng J., Sakata N., Imanaga Y., Tachikawa Y., Chihara J., Takebayashi S. Evidence for a link between glycoxidation and lipoperoxidation in patients with chronic renal failure. Clin. Nephrol. 1999;51:280–289. [PubMed] [Google Scholar]
  • 36.Nawroth P.P., Bierhaus A., Vogel G.E., Hofmann M.A., Zumbach M., Wahl P., Ziegler R. Nichtenzymatische Glykierung und oxidativer Stress bei chronischen Erkrankungen und Diabetes mellitus. Med. Klin. 1999;94:29–38. doi: 10.1007/BF03044692. [DOI] [PubMed] [Google Scholar]
  • 37.Ortwerth B. J., Prabhakaram M., Nagaraj R. H., Linetski M. The relative UV sensitizer activity of purified advanced glycation endproducts. Photochem. Photobiol. 1997;65:666–672. doi: 10.1111/j.1751-1097.1997.tb01909.x. [DOI] [PubMed] [Google Scholar]
  • 38.Traverso N., Menini S., Cottalasso D., Odetti P., Marinari U.M., Pronzato M.A. Mutual interaction between glycation and oxidation during non-enzymatic protein modification. Biochim. Biophys. Acta. 1997;1336:409–418. doi: 10.1016/s0304-4165(97)00052-4. [DOI] [PubMed] [Google Scholar]
  • 39.Costache G., Hasu M., Popov D., Georgescu A. The use of the myograph technique for the investigation of the vascular reactivity. A review. Curr. Problems in cell. and molec.Biol. 1997;2:38–43. [Google Scholar]
  • 40.Frye, E.B., Degenhardt, T.P., Thorpe, S.R., Baynes, J.W.: Role of the Maillard reaction in aging of tissue proteins-Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins. J. Biol. Chem., 273: 18714–18719, 1998. [DOI] [PubMed]
  • 41.Schmidt H.W., Warner T.D., Ischii K., Sheng H., Murad F. Insulin secretion from pancreatic β cells caused by L-arginine-derived nitrogen oxides. Science. 1992;255:721–725. doi: 10.1126/science.1371193. [DOI] [PubMed] [Google Scholar]
  • 42.Pieper G.M. Review of alterations in endothelial nitric oxide production in diabetes. Protective role of arginine in endothelial dysfunction. Hypertension. 1998;31:1047–1060. doi: 10.1161/01.hyp.31.5.1047. [DOI] [PubMed] [Google Scholar]
  • 43.Gumuse B., Tel B.C., Demirdamar R., Sahin Erdemii I. Reactive oxygen species-induced impairment of endothelium-dependent relaxation in rat aortic rings: protection by L-arginine. Eur.J. Pharmacol. 1996;306:107–112. doi: 10.1016/0014-2999(96)00209-9. [DOI] [PubMed] [Google Scholar]
  • 44.Schwarzacher S.P., Lim T.T., Wang B., Kernoff R.S., Niebauer J., Cooke J.P., Yeung A.C. Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after baloon angioplasty. Circulation. 1997;95:1863–1869. doi: 10.1161/01.cir.95.7.1863. [DOI] [PubMed] [Google Scholar]
  • 45.Pieper G.M., Siebeneich W., Moore-Hilton G., Roza A.M. Reversal by L-arginine of a dysfunctional arginine/nitric oxide pathway in the endothelium of the genetic diabetic BB rat. Diabetologia. 1997;40:910–915. doi: 10.1007/s001250050767. [DOI] [PubMed] [Google Scholar]
  • 46.Girao H., Mota M. C., Ramalho J., Pereira P. Cholesterol oxides accumulate in human cataracts. Exp.Eye Res. 1998;66:645–652. doi: 10.1006/exer.1998.0465. [DOI] [PubMed] [Google Scholar]
  • 47.Girao H., Mota M. C., Pereira P. Cholesterol may act as an antioxidant in lens membranes. Curr. Eye Res. 1999;18:448–454. doi: 10.1076/ceyr.18.6.448.5273. [DOI] [PubMed] [Google Scholar]
  • 48.Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976;72:248–255. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the American Aging Association are provided here courtesy of American Aging Association

RESOURCES